AstraZeneca, Pfizer agree to deal for Nexium over-the-counter sales


AstraZeneca announced that it has entered into an agreement with Pfizer Inc. for the over-the-counter  rights for  Nexium, a prescription drug currently approved to treat the symptoms of  serious cases of heartburn.

AstraZeneca has operations in northern Delaware.

Under the terms of the agreement, Pfizer will acquire the exclusive global rights to market Nexium  for the approved over-the-counter indications in the United States, Europe and the rest of the world.

Pfizer will make an upfront payment of $250 million to AstraZeneca and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales.

Click below for the full release:

via AstraZeneca – AstraZeneca and Pfizer enter agreement for over-the-counter NEXIUM; AstraZeneca raises 2012 guidance.

Facebook Comments